A pregnancy-prevention program in women of childbearing age receiving isotretinoin.
BACKGROUND
Isotretinoin is effective in treating severe acne, but it is also teratogenic. To minimize pregnancies among exposed women, the manufacturer, together with the U.S. Food and Drug Administration, implemented a multicomponent Pregnancy Prevention Program in 1988. We report the results of an ongoing survey designed to assess compliance with this program.


METHODS
Treated women enrolled in the survey through their physician, by filling out a form in the medication package, or by calling a toll-free telephone number. They were randomly assigned to be followed by telephone or by mail. Telephone interviews were conducted at the start of therapy, in the middle of it, and 6 months after it ended; mailed questionnaires were completed 6 months after therapy ended (median duration of therapy, 20 weeks).


RESULTS
Between 1989 and 1993, 177,216 eligible women enrolled in the survey. Interviews with 24,503 women within one month of enrollment revealed that 99 percent had been told to avoid pregnancy. At that time, approximately 54 percent were not sexually active (of whom 37 percent used contraception) and 42 percent were sexually active (of whom 99 percent used contraception); 4 percent were infertile. Among 124,216 women with completed telephone or mail follow-up results, there were 402 pregnancies during therapy (3.4 per 1000 courses of isotretinoin); 72 percent of the pregnant women had elective abortions, 16 percent spontaneous abortions, 3 percent ectopic pregnancies, and 8 percent live births.


CONCLUSIONS
The pregnancy rate among women receiving isotretinoin therapy was substantially lower than that in the general population and was compatible with the characteristics and behavior of the enrolled women.
Mitchell
A A
AA
Slone Epidemiology Unit, School of Public Health, Boston University School of Medicine, MA 02146, USA.
Van Bennekom
C M
CM
Louik
C
C
D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control; D000293:Adolescent; D000328:Adult; D002648:Child; D003267:Contraception / Q000706:statistics & numerical data; D003268:Contraception Behavior; D003625:Data Collection / Q000379:methods; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007231:Infant, Newborn; D015474:Isotretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010349:Patient Compliance; D010820:Physicians; D011247:Pregnancy / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires; D013689:Telephone
D015474:Isotretinoin